SIGFOX
6.1.2022 11:02:07 CET | Business Wire | Press release
Sigfox, a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer, today announces its partnership with HT Micron, a Brazilian expert in advanced semiconductor solutions, and Nowi, a semiconductor company that specializes in the development of energy harvesting power management technology, to explore and unlock the benefits of integrating energy harvesting into Sigfox devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005406/en/
This collaboration marks the first step for Sigfox towards a commercial development of energy harvesting modules to equip IoT devices and contribute to more sustainability in IoT. Key use cases are applications in Smart metering, industrial sensoring, asset tracking and air quality monitoring.
During the research phase, HT Micron has worked on creating the innovative semiconductor solution to be integrated with Nowi’s Energy Harvesting PMIC (Power Management Integrated Circuit) designed especially for low power IoT devices. Equipped on Sigfox devices and powered by the 0G technology, this solution will help reduce battery consumption and offer longer autonomy while reducing the total cost of ownership.
Nowi PMIC is designed to efficiently extract power from ambient energy sources like light and vibration to charge a variety of energy storage elements such as a rechargeable battery or a capacitor. It is best suited for most low power applications like distributed IoT sensors and TV remote controls for example.
“The low power consumption of Sigfox solutions is particularly well suited to being powered by ambient energy harvesting. As many Sigfox-based applications require intermittent communication intervals, this allows for trickle charging a storage element with energy harvesting in between transmissions ,” explains Chris Juliano, CCO at Nowi .
Sigfox and HT Micron have been working together for several years already and HT Micron was identified as a strategic partner for this project as they have the expertise to create innovative modules and they consider energy harvesting essential for IoT mass adoption with sustainability.
“We are glad to take this next step with Sigfox and explore energy harvesting solutions as a new way to create added value to our end customers and help them improve their environmental impact ,” says Edelweis Ritt, CIO at HT Micron .
“This collaboration with Nowi and HT Micron is another proof point towards our ambition to create IoT solutions that will help our clients preserve the environment by greatly reducing their energy consumption. We are looking forward to the development of this new kind of devices and to the positive impact they will generate ” says Benjamin Jooris, Client & Ecosystem Success Director at Sigfox.
The first step of this project is a development kit integrating Nowi’s PMIC solution with HT Micron’s Sigfox system-in-package, to be used for testing purposes by R&D and product development teams. First information will be presented at CES 2022 (5-7 January in Las Vegas) at Nowi’s booth (#51733) to gather customer and developers’ feedback. Customers can register to receive the development kit. Next, Sigfox, Nowi and HT Micron will create a mass production module that can be used by any type of device maker.
This announcement comes as part of strengthening Sigfox's strategy to help reduce the human impact on the environment with IoT, and it will be soon followed by other solutions based on energy harvesting as new projects are already in discussion.
****
About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.
ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.
About Nowi
Nowi is a semiconductor company founded in 2016, based in Delft, the Netherlands, with regional offices in the US and in Shanghai.
Nowi has developed energy harvesting power management ICs that combine top harvesting performance with the world’s smallest assembly footprint and lowest BOM cost. Thereby it simplifies the design process and lowers the threshold for any company to develop ‘Plug & Forget’ products.
About HT Micron
HT Micron provides advanced semiconductor solutions. The portfolio includes memories for computers, cell phones and smart TVs, as well as System-in-Package connectivity solutions for the Internet of Things. HT Micron is a Brazilian company, having as the main shareholder the South Korean group HANA Micron, and is based in the city of São Leopoldo, RS, in South Brazil.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom